Liphetho tsa Groundbreaking tsa CD7-Targeted CAR-T Therapy bakeng sa T-ALL le T-LBL

Teko ea morao-rao ea tleliniki e bonts'itse tsoelo-pele e kholo kalafong ea T-cell acute lymphoblastic leukemia (T-ALL) le T-cell lymphoblastic lymphoma (T-LBL) e sebelisang CD7-targeted chimeric antigen receptor (CAR) T cell therapy. . Phuputso, e entsoeng ke sehlopha se tsoang Sepetleleng sa Hebei Yanda Lu Daopei le Lu Daopei Institute of Hematology, e kenyelelitse bakuli ba 60 ba fumaneng tekanyo e le 'ngoe ea lisele tsa T tse khahlanong le CD7 CAR (NS7CAR) tse khethiloeng ka tlhaho.

Liphetho tsa liteko li khothatsa haholo. Ka letsatsi la 28, 94.4% ea bakuli ba fihletse tšoarelo e tebileng e feletseng (CR) mokong oa masapo. Ho feta moo, har'a bakuli ba 32 ba nang le lefu la extramedullary, 78.1% e bontšitse karabelo e ntle, mme 56.3% e fihletse tšoarelo e felletseng mme 21.9% e fihletse tšoarelo e itseng. Kakaretso ea lilemo tse peli tsa ho phela le ho se be le tsoelo-pele e ne e le 63.5% le 53.7%, ka ho latellana.

Kalafo ena e ncha e hlokomeleha bakeng sa boemo ba eona bo laolehang ba polokeho, ka cytokine release syndrome e hlahang ho 91.7% ea bakuli (haholo-holo sehlopha sa 1/2), le neurotoxicity e bonoang ho 5% ea linyeoe. Ho feta moo, phuputso e fumane hore bakuli ba ileng ba tsoela pele ka li-transplants tsa ho kopanya ka mor'a hore ba fihlele CR ba ne ba e-na le litekanyetso tse phahameng haholo tsa ho phela ntle le tsoelo-pele ha li bapisoa le ba sa kang ba etsa joalo.

Khamphani ea rona e ntse e lekola bokhoni ba kalafo ea lisele tsa CD7 CAR-T ka sehlahisoa sa rona, ka sepheo sa ho kenya letsoho ntlafatsong ea kalafo ea mafu a T-cell.

Liphuputso tsena li totobatsa bokhoni ba CD7-targeted CAR-T cell therapy ho fana ka tšepo e ncha bakeng sa bakuli ba nang le T-ALL le T-LBL ea refractory kapa e khutletseng hape, e leng se bontšang ketsahalo ea bohlokoa ntoeng e tsoelang pele khahlanong le mafu ana a phephetsang.